Minimal synthetic genomes: Research, approaches and applications

The organization data lists 2 companies and 1 startup, but does not name them in its company profiles. The named leaders are research organizations, including the J. Craig Venter Institute (JCVI), which developed JCVI-syn3.0. For partner searches, distinguish organizations with documented minimal-genome research from commercial suppliers or developers, which are not identified by name here.

No named manufacturer or supplier is identified in the organization data. The J. Craig Venter Institute is a research institute known for developing JCVI-syn3.0, while Harvard University and the University of Illinois at Urbana-Champaign contribute to research on whole-cell modeling and chromosome organization. These research roles do not establish that an organization offers a commercial product or supply service.

The J. Craig Venter Institute leads work on minimized genomes, including JCVI-syn3.0, while Harvard University and the University of Illinois at Urbana-Champaign contribute to research on JCVI-syn3A. Boston Children’s Hospital and the National Center for Supercomputing Applications are also associated with whole-cell modeling. Shandong University developed CREAT, a CRISPR-based genome-trimming strategy.

The funding data lists $15.3 million across 15 grants since 2020 and $759 million across 4 funding rounds. These totals reflect the funding records associated with the topic, not a dedicated funding program. The listed rounds include university and hospital financing, so they should not be read as funding exclusively for minimal synthetic genome research.

The latest listed funding event is a $500 million Harvard University grant dated October 2025. Other entries include a $39 million private equity round for Harvard University in June 2025, a $20 million National Science Foundation grant in April 2025, and a $200 million Boston Children’s Hospital funding round in March 2025. The data does not establish that each was dedicated solely to this field.

No patent activity is recorded in the 24-month window, and patent growth is not reported. The all-time total is 7 patents, but no patent holders are listed. Recent activity is therefore more visible in publications and research programs than in the recorded patent data; this does not establish whether relevant intellectual property exists outside these records.

October 2026 research examined the physicochemical design, structure and permeability of the JCVI-syn3A membrane and reported unrecognized transporters and immunity factors in JCVI-syn3.0. In September 2026, Shandong University reported CREAT, a CRISPR-based method to identify dispensable genome regions and accelerate genome reduction. These results emphasize cell function as well as gene deletion.

The five listed approaches are essentiality screening, comparative genomics, computational genome design, stepwise genome reduction, and genome synthesis and boot-up. Screening and comparative analysis help identify candidate genes for removal; computational design proposes a reduced genome; stepwise reduction tests deletions in stages; and synthesis and boot-up test whether a designed genome can function in a cell.

The United States leads the recorded activity with 316 documents, followed by China with 118, the United Kingdom with 105, and Germany with 95. Japan and France also have substantial activity, with 52 and 49 documents respectively. The counts indicate where activity is recorded, not a measure of research quality or commercial readiness.

The application data emphasizes synthetic cell research, with 53 documents, and whole-cell modeling, with 39. Biomedical platforms account for 8 documents, while industrial biomanufacturing has 1. Minimal genomes can support studies of cellular function and model development; the recorded activity is much stronger in research and modeling than in reported industrial applications.